Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group 13F holdings
Kahn Brothers Group's Portfolio
- Portfolio value:
- $594.97M≈
- # of securities:
- 52
- Reported for:
- 30 Jun 2024 (Q2)
- Latest filing date:
- 14 Aug 2024
What stocks did Kahn Brothers Group own in 2024 Q2?
What was Kahn Brothers Group's 2024 Q2 portfolio?
Kahn Brothers Group has disclosed a total of 52 security holdings in their (2024 Q2) SEC 13F filing(s) with portfolio value of $594,970,332.
Kahn Brothers Group's portfolio holdings are tracked quarterly based on SEC 13F filings. Snapshots for each reporting period document the full list of disclosed positions and their portfolio allocations.
Kahn Brothers Group's original 13F reports (2024 Q2) are the official SEC institutional disclosure documents covering all reported equity positions.
52 results
| History | Ticker | Name |
% of portfolio |
Shares* |
Reported price* |
% difference current price* |
Value | Held since* | Held for* |
Security type |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Citigroup Inc
|
12.74%
|
1,194,852
|
$63.46
|
+108.08%($132.05)
|
$75,825,496
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
-0.38% (-4.59K)
|
-0.04%
|
|
|
|
Merck & Company Inc
|
12.32%
|
591,911
|
$123.80
|
+6.06%($131.30)
|
$73,278,768
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
-3.57% (-21.9K)
|
-0.4%
|
|
|
|
BP PLC-SPONS ADR
|
9.95%
|
1,640,402
|
$36.10
|
+21.37%($43.82)
|
$59,218,953
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Depositary Receipt
|
-1.51% (-25.22K)
|
-0.14%
|
|
|
|
GlaxoSmithKline PLC ADR
|
8.03%
|
1,241,261
|
$38.50
|
+33.12%($51.25)
|
$47,788,450
|
2014 Q3
|
≈ 10.00 years
|
Depositary Receipt
|
-0.99% (-12.38K)
|
-0.07%
|
|
|
|
Flagstar Financial, Inc
|
6.61%
|
12,211,602
|
$3.22
|
+330.90%($13.88)
|
$39,321,607
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
+96.54% (+6M)
|
+3.25%
|
|
|
|
Organon & Co
|
5.78%
|
1,661,023
|
$20.70
|
-34.56%($13.54)
|
$34,382,763
|
2021 Q2
|
≈ 3.25 years
|
Common Stock
|
+40.74% (+480.82K)
|
+1.67%
|
|
|
|
Bristol-Myers Squibb Company
|
5.77%
|
827,258
|
$41.53
|
+49.54%($62.10)
|
$34,355,534
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
-0.57% (-4.73K)
|
-0.03%
|
|
|
|
Bayer AG PK
|
5.18%
|
4,374,455
|
$7.04
|
+85.94%($13.09)
|
$30,795,897
|
2023 Q4
|
≈ 0.75 years
|
Depositary Receipt
|
+41.15% (+1.28M)
|
+1.51%
|
|
|
|
MBIA Inc
|
5.14%
|
5,570,263
|
$5.49
|
+4.92%($5.76)
|
$30,580,277
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
+7.60% (+393.65K)
|
+0.36%
|
|
|
|
Seaboard Corp
|
4.90%
|
9,225
|
$3,160.78
|
+47.75%($4,670.01)
|
$29,158,160
|
2013 Q2 or earlier
|
≈ 11.25+ years
|
Common Stock
|
+1.91% (+173)
|
+0.09%
|
|
Completely sold out
2 results
| History | Ticker | Name |
Sold shares* |
% change to portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|
|
|
EAGLE BULK SHIPPING INC
|
-4,460
|
-0.04%
|
2024 Q1
|
≈ 0.25 years
|
|
|
|
Glacier Bancorp Inc
|
-6,264
|
-0.04%
|
2024 Q1
|
≈ 0.25 years
|
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.